Norges Bank’s Alaunos Therapeutics TCRT Stock Holding History

Norges Bank’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,399	Closed	-$671K	–	2133
2018 Q3	$671K	Sell	1,399 -2,260	-62%	-$969K	﹤0.01%	2091
2018 Q2	$1.66M	Sell	3,659 -1,800	-33%	-$1.14M	﹤0.01%	2037
2018 Q1	$3.21M	Hold	5,459	–	–	﹤0.01%	1956
2017 Q4	$3.39M	Hold	5,459	–	–	﹤0.01%	1923
2017 Q3	$5.03M	Hold	5,459	–	–	﹤0.01%	1866
2017 Q2	$5.09M	Sell	5,459 -1,465	-21%	-$1.44M	﹤0.01%	1880
2017 Q1	$6.58M	Hold	6,924	–	–	﹤0.01%	1841
2016 Q4	$5.56M	Hold	6,924	–	–	﹤0.01%	1845
2016 Q3	$5.58M	Buy	6,924 +2,058	+42%	+$1.65M	﹤0.01%	1854
2016 Q2	$4.01M	Hold	4,866	–	–	﹤0.01%	1917
2016 Q1	$5.42M	Hold	4,866	–	–	﹤0.01%	1801
2015 Q4	$6.07M	Buy	4,866 +1,124	+30%	+$1.86M	﹤0.01%	1814
2015 Q3	$5.06M	Buy	+3,742	New	+$6.18M	﹤0.01%	1842

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Norges Bank's TCRT Position: Q4 2018 in Review

Norges Bank sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 1,399 shares — an estimated $671K sold.

Norges Bank first reported a position in TCRT in Q3 2015 and held it in 13 quarters. The position peaked at $6.58M in Q1 2017. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

Norges Bank reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
Norges Bank sold 1,399 Alaunos Therapeutics shares in Q4 2018, an estimated $671K.
Norges Bank first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 13 quarters.
Norges Bank's Alaunos Therapeutics position peaked at $6.58M in Q1 2017.
137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Norges Bank's 13F filing for Q4 2018, filed 8 Feb 2019.